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Acute and chronic graft-versus-host disease
(aGVHD, cGVHD) remain the major clinical compli-
cation of allogeneic hematopoietic cell transplantation
(HCT) limiting survival and inducing major morbid-
ity, sometimes for several years posttransplant. In
this article, 3 authors review components of GVHD
that underlie these hazards. Dr. Pavan Reddy outlines
preclinical, mostly murine data detailing the current
understanding of the pathophysiology of aGVHD.
cGVHD, the major ongoing immunologic limitation
to transplant success has complexities in its assessment
and management, and unfortunately, no defined best
therapy. Dr. Mukta Arora outlines new strategies for
its assessment and describes opportunities for better
treatment of this chronic disease. Finally, it is well rec-
ognized that aGVHD and cGVHD induce their mor-
bidity, not just by their end-organ toxicity or the side
effects of treatment, but the syndrome in itself is im-
munosuppressive. cGVHD compromises the develop-
ment of functional defenses against infection, and may
alter defenses against recurrence of any underlying
cancer. Drs. Guimond and Mackall review the impact
of GVHD on the immune development post HCT,
and in doing so, outline ways that therapeutical alter-
nativesmight better facilitate immunologic reconstitu-
tion.
Mouse models have been central to our identifica-
tion and understanding of the pathophysiologic mech-
anisms of GVHD, and canine models have been
critical to the development of clinically useful strate-
gies for GVHD prophylaxis and treatment [1]. Based
largely on these experimental models, the develop-
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6/j.bbmt.2008.10.014steps or phases: (1) activation of the antigen presenting
cells (APCs); (2) donor T cell activation, proliferation,
differentiation, and migration; and (3) target tissue de-
struction [2].Phase I: Activation of APCs
The first step involves the activation of APCs by
the damage from underlying disease and the HCT
conditioning regimen. Damaged host tissues respond
by producing ‘‘damage associated/danger’’ signals, in-
cluding proinflammatory cytokines (eg, interleukin
[IL]-1, IL-6, tumor necrosis factor-alpha [TNF-a]),
chemokines, and increased expression of adhesion
molecules, major histocompatibility complex (MHC)
antigens and costimulatory molecules on host APCs
[1]. Damage to gastrointestinal (GI) tract from condi-
tioning is particularly important because it allows for
systemic translocation of additional inflammatory
stimuli such as microbial products including lipopoly-
saccharides (LPS) or other pathogen-associated mo-
lecular patterns that further enhance the activation of
host APCs [3]. The secondary lymphoid tissue in the
GI tract is likely the initial site of interaction between
activated APCs and donor T cells, but secondary lym-
phoid tissues are not obligatory for the induction of
GVHD [4,5]. These observations have to in part led
tp clinical strategy of reducing the intensity of the con-
ditioning regimen [6]. The concept that enhanced ac-
tivation of host APCs increases the risk for aGVHD
unifies a number of seemingly disparate clinical associ-
ations with that risk, such as advanced stages of malig-
nancy, more intense transplant conditioning regimens,
and histories of viral infections. Experimental GVHD
can also be reduced by manipulating distinct subsets of
APCs [7]. Both the host- and donor-derived hemato-
poietic APC subsets are relevant for the induction
and severity of aGVHD [8]. However, certain APC
subsets have been shown to mitigate GVHD [9], and,
in addition, nonhematopoietic stem cells, such as mes-
enchymal stromal cells, acting as APCs can reduce al-
logeneic T cell responses and ameliorate GVHD. The
mechanism for such inhibition however remains un-
clear [10]. The receptors and signaling pathways that
are critical for the activation of APCs and induction
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dancy, the critical receptors/ pathways might vary
depending on the type of bone marrow transplant
(BMT), the preparative regimen, and the other rele-
vant host/donor conditions. Recent clinical observa-
tions suggest that certain polymorphisms that affect
APC activation, such as donor host NOD2 and donor
inflammasome protein-encoding variants in NLRP2
and NLRP3, might be relevant [11,12].Phase II: Donor T Cell Activation
The core of the GVH reaction is Step 2, where
donor T cells proliferate and differentiate in response
to host histoincompatible antigens presented by the
APCs [8]. The damage associated signals generated
in Phase I augment /donor T cell responses to host an-
tigens by increasing the expression of ‘‘secondary sig-
nals,’’ the costimulatory molecules, and by the
secretion of various ‘‘tertiary signals,’’ the proinflam-
matory cytokines [2,13]. Blockade of costimulatory
pathways to prevent GVHD is successful in animal
models, but this approach has not yet been tested in
large clinical trials [1].
Several T cell subsets have been shown to be im-
portant in causing, amplifying, perpetuating, or regu-
lating aGVHD. In mouse models, where genetic
differences between donor and recipient strains can
be tightly controlled, CD41 cells induce aGVHD to
MHC class II differences, and CD81 cells induce
aGVHD toMHC class I differences [14]. In themajor-
ity of HLA-identical HCTs, both CD41 and CD81
subsets respond to minor histocompatibility antigens
and can cause GVHD in HLA-identical HCT. Naı¨ve
donor T cells cause GVHD. By contrast, memory sub-
sets from the donors are less efficient in inducing
GVHD [8]. However, alloreactive memory subsets
that develop in the host have been shown to perpetuate
GVHD [15]. Regulatory T cells (Tregs) can suppress
the proliferation of conventional T cells and prevent
GVHD in animal models when added to donor grafts
containing conventional T cells [16], although host-
type regulatory T cells have also been shown to miti-
gate GVHD in certain models [8]. Natural Killer T
cell (NKT) 1.11 subsets of both the host and donors
that have also been shown to modulate aGVHD [17].
A recent clinical trial of total lymphoid irradiation
(TLI) used as conditioning significantly reduced
GVHD and enhanced host NKT cell function [18].
Th1 cells (interferon-gamma [IFN]-g, IL-2, and
TNF-a) aggravate or regulate aGVHD depending
on the model system. Nonetheless, IL-2 production
by donor T cells remains the principal target of
many current clinical therapeutic and prophylactic ap-
proaches to GVHD, such as calcineurin inhibitors
(CNIs) cyclosporine (CsA), tacrolimus, and monoclo-
nal antibodies (mAbs) directed against IL-2 and itsreceptor [19]. In this context, it is important to note
that CNIs mediate effects other than T cell activation..
But emerging data indicate an important role for IL-2
in the generation and maintenance of CD41CD251
Tregs, suggesting that prolonged interference with
IL-2 may have an unintended consequence of prevent-
ing the development of long-term tolerance after
allogeneic HCT [20]. Likewise, the role of Th2 polar-
ization also is likely to be dependent on the type of
model. Emerging data suggest that Th17 (IL-17A) po-
larization does not appear to be specifically pathogenic
for GVHD. However, whether T cell polarization
causes distinct target tissue damage with a varied path-
ogenic response remains incompletely understood and
explored.
Phase III: Cellular and Inflammatory Effector
Phase
The effector phase of this process is a complex cas-
cade of both cellular mediators such as cytotoxic T
lymphocytes (CTLs) and NK cells and soluble inflam-
matory mediators such as TNF-a, IFN-g, IL-1, and
nitric oxide [1,21]. These soluble and cellular media-
tors synergize to amplify local tissue injury and further
promote inflammation and target tissue destruction.
The cellular effectors of aGVHD are primarily
CTLs and NK cells [3]. CTLs that preferentially use
the Fas/FasL pathway of target lysis and appear to pre-
dominate in GVHD liver damage (hepatocytes express
large amounts of Fas), whereas GVHD CTLs that use
the perforin/granzyme pathways are more important
in the GI tract and skin [1,22]. It is relevant to note
that although hepatocytes are the dominant targets
of injury inmurinemodels, the bile duct epithelial cells
are the primary targets of humanGVHD.Chemokines
direct the migration of donor T cells from lymphoid
tissues to the target organs where they cause damage.
Chemokines are overexpressed as a result of inflamma-
tion, and enhance the homing of cellular effectors to
target organs during experimental GVHD [1,23,24].
Expression of integrins, such as a4b7 and its ligand
MadCAM-1, are also important for homing of donor
T cells to Peyer’s patches during intestinal GVHD
[1]. Microbial products such as LPS and others that
leak through a damaged intestinal mucosa or skin
may stimulate secretion of soluble mediators, such as
inflammatory cytokines [3,25]. The GI tract is partic-
ularly susceptible to damage from TNF-a, and plays
a major role in the amplification and propagation of
the ‘‘cytokine storm’’ characteristic of aGVHD [3].
Nonetheless, the reasons for the unique specificity of
aGVHD target organs remain unclear.
Future Studies
Experimental studies from the past few years
have allowed for a more refined understanding of the
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cation of a number of new cell types that have an
impact upon GVHD. The next few years will un-
doubtedly bring these heterogenous and perhaps addi-
tional cell types into greater focus, so that we can
identify and isolate them with greater precision, and
understand factors that stimulate or repress. Advances
in understating the basic biology of the chronicity of
inflammatory processes, the cellular interactions and
molecular pathways of tolerance, the mechanisms for
target organ and leukemia sensitivity /specificity, the
genomic and proteomic profiling analyses will add tex-
ture and refinement to our understanding of GVHD.NOVELTHERAPIES FOR CGVHD
cGVHD is the major cause of late morbidity and
mortality post-HCT. Traditionally, corticosteroids
along with calcineurin inhibitors have been the main-
stay of therapy for cGVHD. However, recently there
has been renewed interest in treatment of this disease,
and several new agents have been the focus for both
primary treatment and treatment of steroid refractory
or dependent disease.
Pathophysiology of cGVHD
The pathophysiology of cGVHD is less well un-
derstood than the pathophysiology of aGVHD. Allo-
reactive T cells are believed to be responsible for
manifestations of cGVHD. Both CD41 and CD81
T cells have been implicated as primary mediators of
cGVHD, and data support the role of dendritic cells
as well [26]. This is based upon the hypothesis that
the donor immune system recognizes antigens other
than human leukocyte antigen (HLA) as targets of at-
tack. Differences in these antigens (mHAs) between
donor and host form the basis of the immune attack.
Previously characterized mHAs in humans include
both autosomal and Y-chromosome coded (H-Y) anti-
gens. Other factors implicated in the pathogenesis are
B cells and certain cytokines, TNF and IFN-g, and T
regulatory cells.
Initial Systemic Therapy
Several studies document response rates of about
50%-55% [27] with 25%-50% [27,28] requiring pro-
longed immunosuppression beyond 4 years. Compli-
cations arise as a result of both active disease and
prolonged systemic immunosuppression contributing
to the high morbidity and mortality. Several studies
are evaluating new agents either as initial therapy or
in patients with steroid refractory or dependent disease
to improve response and survival in these patients.
A combination of prednisone with calcineurin
inhibitor has been the standard initial therapy for
cGVHD based upon earlier reports documentingimproved survival using combination therapy versus
prednisone alone [29]. However, in a more recent ran-
domized comparison of CsA and prednisone versus
prednisone in patients with platelet count .100,000/
mL [28], similar rates of discontinuation of immuno-
suppression, requirements of secondary immunosup-
pressive therapy, and mortality were seen [28].
Two randomized, double-blind multicenter trials
tested newer agents (hydroxycholoroquine [P.I.: A.L.
Gilman, University of North Carolina, Chapel
Hill] or mycophenolate mofetil [MMF; P.I.: Paul
Martin, Fred Hutchinson Cancer Research Center,
Seattle]) added to standard treatment to improve out-
comes in cGVHD, and we await presentation of their
results.
Salvage Therapy
There is no standard second-line therapy for pa-
tients with cGVHD. Several agents have been tested
in case series and small phase II trials. The studies
are heterogeneous in patient population selection
and definition of response criteria. The NIH Consen-
sus working group has proposed incorporation of
newer, more objective measures of patient selection
for trials as well as cleaner definition of response.
This should improve the quality and comparability
of data for studies testing salvage therapy for cGVHD.
MMF
Several studies have documented response rates of
46%-75% in steroid refractory disease. Baudard et al.
[30] reported similar high response rate of 69%, but
observed higher rates of opportunistic infections.
Higher serum trough levels of mycophenolic acid
were associated with improved response rate.
Rituximab
B cells may be implicated in the pathogenesis of
cGVHD, as is evidenced by antibody production
against sex-mismatched, Y chromosome encoded mi-
nor HLA antigens in association with cGVHD. Cutler
et al. [31] tested rituximab in a phase I/II study in re-
fractory cGVHD. The drug was well tolerated, and
toxicity was limited to infectious events. The clinical
response rate was 70%. The results of these prelimi-
nary studies highlight potential activity of Rituximab
with particularly high efficacy for skin and musculo-
skeletal involvement including scleroderma.
Sirolimus
Sirolimus is a macrocyclic triene antibiotic with
immunosuppressive, antitumor, and antifungal prop-
erties. Sirolimus prevents T and B cell activation by
cytokines, which in turn, prevents cell cycle progres-
sion and proliferation. Efficacy of sirolimus in refrac-
tory cGVHD was tested in a phase II trial by Couriel
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adverse events were hyperlipidemia, renal dysfunc-
tion, cytopenias, and infectious complications. Throm-
botic microangiopathy developed in 4 cases. This is
likely related to higher sirolimus levels that exaggerate
vascular toxicity of calcineurin inhibitors. When used
together, serum levels of both agents must be moni-
tored carefully and maintained in a lower therapeutic
range.
Extracorporeal Photopheresis (ECP)
ECP is a technique where lymphocytes collected
by apheresis are exposed to PUVA. Several mecha-
nisms have been proposed to explain the efficacy of
ECP, including induction of lymphocyte apoptosis,
changes in dendritic cell differentiation and function,
induction of regulatory T cell subsets, synthesizing
IL-10, and, in the long term, restoration of the DCI/
DC2 and T helper 1 (Th1)/Th2 balance in favor of
DC2/Th2 [33]. In a prospective randomized trial of
ECP 1 standard therapy versus standard therapy
alone, in patients with steroid nonresponsive skin
GVHD, no benefit favoring ECP was seen in total
skin scores at the end of 12 weeks; however, the pro-
portion of patients who had at least a 25% decrease
from baseline in total skin score and at least a 50%
reduction in steroid dose was significantly higher in
the ECP arm [34]. In a report by Couriel et al. [33],
71 patients with steroid-resistant cGVHDwere treated
with ECP. The overall response rate was 61%. These
results support responsiveness of both skin and visceral
disease in ECP.
High-dose steroids
In a study by Akpek et al. [35], 61 patients with se-
vere refractory cGVHD were treated with methyl-
prednisone at 10 mg/kg/ day for 4 consecutive days.
Major and minor response was seen in 48% and 27%
of patients. The treatment was well tolerated with no
serious adverse events.
Pentostatin
In a report by Jacobsohn et al. [36], 58 patients
with steroid refractory cGVHD were given pentosta-
tin 4 mg/m2 i.v. every 2 weeks for 12 doses. Of 58 pa-
tients, 32 (55%) had an objective response. Infection
was the most significant toxicity.
Hydroxychloroquine
Hydroxychloroquine is a 4-aminoquinoline anti-
malarial drug used for the treatment of autoimmune
diseases. Forty patients with steroid-resistant or ste-
roid-dependent cGVHD were treated with hydroxy-
chloroquine [37]. A response rate of 53% was seen.
No major toxicity (including retinal) was reported
with hydroxychloroquine.Oral Beclomethasone
An enteric-coated oral formulation of corticoste-
roid beclomethasone may have some topical activity
in GI GVHD. A recent randomized trial tested the
drug in GI aGVHD [38]. Patients were randomized
to receive oral beclomethasone versus placebo. There
was a reduction in risk of treatment failure (although
not statistically significant) at day 50.
Thalidomide
Thalidomide has known immunomodulatory prop-
erties and has been used in treatment of refractory
cGVHD. In a trial of 80 patients with refractory
GVHD [39] treated with thalidomide, 20% of patients
responded. Thirty-six percent discontinued the medi-
cation because of side effects, which included sedation,
constipation, neuritis, skin rash, and neutropenia.
Other strategies that have been reported include
pulse cyclophosphamide (Cy), clofazimine, etretinate,
daclizumab, etanercept, alemtuzumab, low-dose meth-
otrexate (MTX), TLI, and mesenchymal stem cell
infusion.Supportive Care
A multidisciplinary approach to management of
patients with cGVHD is needed. Potential side effects
of treatment include infections, osteoporosis, hyper-
tension, hyperglycemia, renal insufficiency, and hyper-
lipidemia. In addition, the disease is associated with
reduced quality of life and psychosocial disturbances.
Appropriate care of these patients requires antimicro-
bial prophylaxis against encapsulated bacteria, pneumo-
cystis pneumonia, cytomegalovirus (CMV), varicella
zoster (VZV), and herpes simplex viruses (HSV; in
patients at risk), and antifungal prophylaxis. Nutritional
support and physical therapy are important components
of their treatment. Considerable attention and subspe-
cialty opinionmay be required for management of these
patients.Agenda for Future Studies
Data regarding cGVHD are difficult to interpret
because of heterogenous patient population, small
sample size, retrospective study design, and inconsis-
tent definitions for diagnosis and response. The NIH
Consensus working group has proposed incorporation
of newer, more objective measures of patient selection
for trials as well as cleaner definition of response.
Future studies should incorporate and test these new
criteria. Definitive evaluation of salvage therapy for
CGVHD requires prospective controlled studies.
A prospective multicenter phase II /III randomized
trial in patients nonresponsive to initial therapy is
planned through the Blood and Marrow Transplant
Clinical Trials Network (BMT CTN).
Table 1. Selected Studies of Novel Agents as Secondary Therapy in cGVHD
Study Novel Therapy Sample Size Response Survival (follow up)
Lopez et al. [40] MMF 24 75% 85% (2 years)
Baudard et al. [30] MMF 15 69% 80% (19.5 months)
Mookerjee et al. [41] MMF 26 46% —
Ratanatharathorn et al. [42] Rituximab 8 50% 100% (27-99 months)
Cutler et al. [31] Rituximab 21 70% —
Couriel et al. [32] Sirolimus 35 63% 41% (2 years)
Jurado et al. [43] Sirolimus 47 81% 57% (3 years)
Flowers et al (randomized
trial of ECP versus no ECP) [34]
ECP 95 Improvement in skin
score 14.5% in
ECP arm vs 10.4% in
non ECP arm (NS)
98% in ECP arm,
94% in non ECP arm
(12 weeks)
Couriel et al. [33] ECP 71 61% 53% (1 year)
Gilman et al. [37] Hydroxychloroquine 40 53% 75% in responders,
40% in nonresponders
(30 months)
Akpek et al. [35] Pulsed steroids 61 75% 81% (2 years)
Jacobsohn et al. [36] Pentostatin 58 55% 70% (2 years)
Browne et al. [44] Thalidomide 37 38% 41% (2years)
Parker et al. [39] Thalidomide 80 20% 53% (2.7 years)
MMF indicates mycophenolate mofetil; ECP, extracorporeal photophoresis; cGVHD, chronic graft-versus-host disease.
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RECONSTITUTION FOLLOWING
ALLOGENEIC HCT
Allogeneic HCT recipients often experience pro-
found, long-lasting lymphopenia, rendering them vul-
nerable to infections and potentially to disease
recurrence. GVHD remains a serious and common
complication of allogeneic HCT, and the adverse ef-
fects of GVHD on immune reconstitution greatly ex-
aggerate the immunodeficiency associated with HCT.
In addition to the immunosuppressive treatments ren-
dered to treat GVHD, current models hold that the
adverse impact of GVHD on immune reconstitution
relates to 3 primary factors: (1) GVHD-mediated
damage to the microenvironment of the thymus and
marrow, which are critical for T and B cell immune
reconstitution, respectively; (2) clonal exhaustion,
senescence, and bystander apoptosis of mature T cells
during aGVHD; (3) disruption of the peripheral niche
responsible for homeostatic expansion and survival of
naı¨ve peripheral CD41 and CD81 T cells.
GVHD-Mediated Damage to Lymphopoietic
Microenvironments
Regeneration of lymphocytes occurs via thymo-
poiesis, which recapitulates thymic ontogeny and
regenerates TCR diversity and/or via thymic-indepen-
dent ‘‘homeostatic peripheral expansion,’’ wherein
mature T lymphocytes extensively proliferate and par-
tially replenish their number, albeit with diminished
repertoire diversity. Thymopoiesis occurswithin a spe-
cialized microenvironment comprised of (1) thymic
epithelium that serves as a source of growth factors
and MHC presentation for thymic selection, (2) mar-
row-derived, early T cell progenitors, and (3) other
thymic stromal elements (eg, adipose tissue, neuralcells, and hormonally responsive elements). MHC ex-
pression on thymic epithelium renders it a prime target
for T cell-mediated alloreactivity and as a result, the
thymus is a primary target organ of aGVHD.
GVHD-associated thymic toxicity is further com-
pounded by preparative regimen- and age-associated
thymic toxicity, resulting in absent thymic function
in most patients with GVHD. Similarly, B cell devel-
opment within the bursal equivalent of the bone mar-
row requires a specialized microenvironment, which is
significantly damaged in the long term by even a lim-
ited course of aGVHD. Thus, GVHD-induced dam-
age to lymphopoietic microenvironments within the
thymus and bursal equivalent in the marrow greatly
diminishes T and B cell immune reconstitution follow-
ingHCT. Although keratinocyte growth factor (KGF)
has shown promising effects in preventing GVHD-
mediated thymic damage, it remains unclear whether
KGF or other therapies can reverse GVHD-induced
damage.Clonal Exhaustion, Senescence, and Bystander
Apoptosis of Mature T Cells during aGVHD
The pathophysiologic processes that initiate
aGVHD have been extensively studied. Fundamental
elements include preparative regimen related tissue
damage, LPS leakage across the gut mucosa, pro-
inflammatory cytokine release, and T cell-mediated
alloreactivity. Early after HCT, homeostatic T cell ex-
pansion in response to a broad array of self-antigens
can provide substantial immune competence. During
aGVHD, however, alloreactive T cells dominate this
process, undergoing dramatic expansion and inducing
severe skewing of the T cell repertoire. This phase of
profound activation and expansion is followed by
widespread apoptosis. Preclinical models have
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tive (eg, bystander) populations undergo apoptosis
during aGVHD, resulting in diminished peripheral
Tcell numbers andwidespread immunedysfunction [45].
Recent studies have demonstrated that IL-7 is
required for homeostatic T cell expansion, and that
IL-7 therapy can enhance immune reconstitution
following HCT. On the other hand, murine models
have shown that IL-7 is required for GVHD induc-
tion, that pharmacologic levels of IL-7 lower the T
cell number required to induce GVHD, and that IL-
7 neutralization can diminish and/or prevent GVHD
[46,47]. Moreover, a recent clinical study demon-
strated that high levels of IL-7 on day 14 following
nonmyeloablative stem cell transplant is a potent pre-
dictive factor of GVHD [48]. Thus, IL-7 appears to
be play important roles both in facilitating immune
reconstitution via homeostatic expansion as well as
a potential cofactor in the development of GVHD.Disruption of the Peripheral Niche Responsible
for Homeostatic Expansion and Survival of
Naı¨ve Peripheral CD41 and CD81 T Cells
Survival of mature T cells requires continuous ac-
cess to self-MHC molecules (Class II for CD41 and
Class I for CD81 cells) and homeostatic cytokines
(IL-7 for naı¨ve cells and IL-15 and/or IL-7 for mem-
ory cells) within the context of a peripheral niche.
The diminished efficiency of CD41 versus CD81 ho-
meostatic peripheral expansion raises the prospect that
the more limited distribution of MHC Class II, which
is essential for the CD41 niche, may limit CD41 ho-
meostatic peripheral expansion, whereas the broadly
available MHC Class I, which is essential for the
CD81 niche, may permit more efficient CD81 expan-
sion in this setting. Animal studies have recently pro-
vided functional data to suggest that GVHD-induced
impairment of the peripheral niche may be a more
important factor in limiting immune reconstitution
than clonal exhaustion and immune senescence of the
T cells themselves [49,50], because T cells obtained
from GVHD hosts expand considerably in non-
GVHD recipients, but not in recipients with GVHD.
The specific cells necessary for the peripheral CD41
niche have not been defined, but following HCT, my-
eloid DCs recover early, whereas the recovery of plas-
macytoid DCs (pDCs) requires months or years [50].
Furthermore, patients with grade III-IV GVHD
show reduced pDCs, which correlate with low CD4
counts [51-56]. Similar findings were made in the set-
ting of HIV infection, where an inability to regenerate
their CD4 T cells may correlate with diminished
pDCs. Thus, emerging science raises the prospect
the some component of GVHD induced impairment
of immune reconstitution may relate to damage to
the peripheral T cell niche in general and the CD41T cell niche in particular. Future studies that more ac-
curately define the critical elements within the CD41
niche required for survival of mature CD41 T cells
could open the way to more effective therapies to aug-
ment immune reconstitution following HCT.ACKNOWLEDGMENTS
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